Liver tumors were induced in the toads, Bufo regularis, in 16 out of 50 cases by the administration of 0.2 mg DMBA/toad, 3 times/week for 12 weeks. Light and electron microscopic photographs demonstrate that these hepatocytes of DMBAtreated toads showed criteria of malignancy. In contrast, toads treated with DMBA at the same dose level and 0.005 percent w/w indomethacin/toad, 3 times/week for 12 weeks showed a lower incidence of liver tumors, 8 out of 50 cases. The biochemical analysis showed that the activity of G6PD, LDH, acid phosphatase and alkaline phosphatase enzymes were decreased in animals treated with DMBA and indornethacin in comparison with toads treated with DMBA alone. It is concluded that indomethacin has an inhibitory effect on hepatocarcinogenesis in toads.